A Study to Investigate the Biological Effects of Saruparib (AZD5305), Darolutamide, and in Combination in Men with Newly Diagnosed Prostate Cancer.

Trial Identifier: D9721C00002
Sponsor: AstraZeneca
Start Date: September 2023
Primary Completion Date: February 2026
Study Completion Date: February 2026
Condition: Prostate Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
AU Melbourne, AU, VIC 3000
AU South Brisbane, AU, 4101
CA, BC Vancouver, BC, CA, V5Z 1M9
CA, ON Toronto, ON, CA, M5G 2M9
CA, QC Québec, QC, CA, G1J 4Z1
ES Barcelona, ES, 8035
ES Barcelona, ES, 08036
ES Madrid, ES, 28041
ES Valencia, ES, 46009
GB Cambridge, GB, CB2 0QQ
GB Manchester, GB, M20 4BX
GB Newcastle upon Tyne, GB, NE7 7AF
NL Amsterdam, NL, 1066CX
NL Nijmegen, NL, 6525 GA
US, MI Detroit, MI, US, 48202
US, RI Providence, RI, US, 02903